{"id":"bendamustine-lenalidomide-rituximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bendamustine is a nitrogen mustard alkylating agent that induces DNA cross-links and strand breaks, leading to cell death. Lenalidomide enhances T-cell and natural killer cell activity, and also has immunomodulatory effects. Rituximab binds to CD20 on B cells, leading to their depletion and reduction of B-cell mediated inflammation.","oneSentence":"Bendamustine is a chemotherapy medication that works by interfering with DNA replication, Lenalidomide is an immunomodulatory drug that affects the immune system, Rituximab is a monoclonal antibody that targets CD20 on B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:49.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":"MZL","enrollment":131},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT07208981","phase":"PHASE2","title":"Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-14","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":169},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT01476787","phase":"PHASE3","title":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-12-29","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT05848765","phase":"PHASE2","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-09-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":284},{"nctId":"NCT02733042","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-11","conditions":"Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":106},{"nctId":"NCT01216683","phase":"PHASE2","title":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-09","conditions":"Lymphoma","enrollment":289},{"nctId":"NCT01754857","phase":"PHASE2","title":"Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-11-12","conditions":"Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin","enrollment":36},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT04882163","phase":"PHASE1, PHASE2","title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2021-10-10","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT04842318","phase":"PHASE4","title":"Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-03-01","conditions":"Follicular Lymphoma","enrollment":789},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT00889798","phase":"","title":"Tumor Registry of Lymphatic Neoplasia","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2009-04","conditions":"Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)","enrollment":3795},{"nctId":"NCT00899431","phase":"PHASE2","title":"Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-05-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":39},{"nctId":"NCT00974233","phase":"PHASE2","title":"Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":34},{"nctId":"NCT01754870","phase":"PHASE2","title":"Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2013-11","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":""},{"nctId":"NCT01429025","phase":"PHASE1","title":"Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-05","conditions":"Refractory/Relapsed Indolent Non-Hodgkin Lymphoma","enrollment":26},{"nctId":"NCT00987493","phase":"PHASE1, PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2009-09","conditions":"Lymphoma","enrollment":49},{"nctId":"NCT01558167","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2011-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":22},{"nctId":"NCT00963534","phase":"PHASE1, PHASE2","title":"Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2009-09","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT01737177","phase":"PHASE2","title":"Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07-31","conditions":"Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT01400685","phase":"PHASE1","title":"Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B Chronic Lymphocytic Leukemia","enrollment":34},{"nctId":"NCT00864942","phase":"PHASE1","title":"Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2009-02","conditions":"Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma","enrollment":28},{"nctId":"NCT01465230","phase":"PHASE2","title":"Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Yale University","startDate":"2012-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bendamustine, Lenalidomide, Rituximab","genericName":"Bendamustine, Lenalidomide, Rituximab","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bendamustine, Lenalidomide, and Rituximab are used to treat various types of lymphoma, including Chronic Lymphocytic Leukemia, Relapsed or Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma. Rituximab, a B-lymphocyte antigen CD20 binding agent, is an antibody that targets and binds to CD20, a protein found on the surface of B cells.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}